ScreenerHero
HNSAHansa Biopharma AB (publ)
STO · SE · Healthcare · Biotechnology · hansabiopharma.com
41.74SEK+2.71%Mkt Cap: 398.19M $P/E: —

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company…

Industry Peers

Biotechnology
Screen all
VX1
Vertex Pharmaceuticals Incorporated
$130.23BUSDP/E 32.1
VRTX
Vertex Pharmaceuticals Incorporated
$139.84BUSDP/E 32.2
REGN
Regeneron Pharmaceuticals, Inc.
$85.11BUSDP/E 20.4
MRNA
Moderna, Inc.
$69.62BUSD
ARGX
argenx SE
$61.34BUSDP/E 39.8
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$46.01BUSD
ONC
BeOne Medicines AG
$41.76BUSDP/E 66.2
RPRX
Royalty Pharma Plc Class A
$35.67BUSDP/E 33.2
ALNY
Alnylam Pharmaceuticals, Inc.
$32.46BUSDP/E 42.3
INSM
Insmed Incorporated
$28.53BUSD
22UA
BioNTech SE
$26.14BUSD
INCY
Incyte Corporation
$25.79BUSDP/E 16.2
GMAB
Genmab A/S
$20.83BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$17.03BUSDP/E 20.0
BBIO
BridgeBio Pharma, Inc.
$16.41BUSD
EXEL
Exelixis, Inc.
$13.48BUSDP/E 17.1
BMRN
BioMarin Pharmaceutical Inc.
$13.42BUSDP/E 187.4
CORT
Corcept Therapeutics Incorporated
$12.87BUSDP/E 264.5

Key Statistics

Company
Market Cap398.19M $
Enterprise Value441.59M $
Revenue (TTM)18.12M $
Gross Profit13.27M $
Net Income (TTM)-51.09M $
Revenue/Share0.1857 USD
Last Price41.74 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees131
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0002148817
Valuation
P/E (Trailing)—
P/E (Forward)-5.53
PEG—
EV/EBITDA-8.09
EV/Revenue24.37
P/S21.47
P/B-7.98
EPS (TTM)-7.65
EPS (Forward)-7.37
52W Range
23.5290% of range43.80
52W High43.80 SEK
52W Low23.52 SEK
Profitability
Gross Margin62.41%
Oper. Margin-334.87%
EBITDA Margin0.00%
Profit Margin-240.30%
ROE600.18%
ROA-45.78%
Growth
Revenue Growth-2.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-52.53M $
CapEx (TTM)—
FCF Margin-141.70%
FCF Yield-6.45%
Net Debt46.01M $
Net Debt/EBITDA-0.84
Balance Sheet
Debt/Equity-10.55
Current Ratio1.25
Quick Ratio1.23
Book Value/Sh-5.1120 SEK
Cash/Share5.432 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)73.00 SEK
Upside (mean)+74.9%
Target Range36.00 SEK – 103.00 SEK
SEK36.00+74.9% to meanSEK103.00
# Analysts8
Ownership
Shares Out.99.73M
Float65.80M
Insiders6.19%
Institutions48.56%
Technical
SMA 5035.25 (+18.4%)
SMA 20032.68 (+27.7%)
Beta1.58
S&P 52W Chg18.16%
Avg Vol (30d)776.24K
Avg Vol (10d)788.80K
Technical Indicators
RSI (14)59.9
MACD1.9782
MACD Signal1.6218
MACD Hist.+0.3564
BB Upper44.57 SEK
BB Middle37.80 SEK
BB Lower31.03 SEK
BB Width35.83%
ATR (14)2.425 SEK
Vol Ratio (20d)0.30x